Zollinger-Ellison syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
 
(3 intermediate revisions by 2 users not shown)
Line 3: Line 3:
{{CMG}} {{AE}} {{MJK}}
{{CMG}} {{AE}} {{MJK}}
==Overview==
==Overview==
The incidence of [[gastrinoma]], which can cause Zollinger-Ellison syndrome, is approximately 0.05-0.2 per 100,000 individuals worldwide. About 25 to 30 percent of [[Gastrinoma|gastrinomas]] are caused by  [[multiple endocrine neoplasia type 1]] ([[MEN1]]).
The incidence of [[gastrinoma]], which can cause Zollinger-Ellison syndrome, is approximately 0.05 - 0.2 per 100,000 individuals worldwide. About 25 to 30 percent of [[Gastrinoma|gastrinomas]] are caused by  [[multiple endocrine neoplasia type 1]] ([[MEN1]]).


==Epidemiology and Demographics==
==Epidemiology and Demographics==


===Incidence===  
===Incidence===  
*The worldwide incidence of [[Gastrinoma|gastrinomas]] is about 5 to 30 cases per 100,000 individuals per year. With improved techniques for tumor detection, the annual incidence has increased. About 80% to 90% of these tumors arise in the so-called “gastrinoma triangle". <ref name="pmid28722872">{{cite journal |vauthors=Cingam S, Karanchi H |title= |journal= |volume= |issue= |pages= |year= |pmid=28722872 |doi= |url=}}</ref>
*The worldwide incidence of [[Gastrinoma|gastrinomas]] is about 5 to 30 cases per 100,000 individuals per year.<ref name="pmid28722872">{{cite journal |vauthors=Cingam SR, Karanchi H |title= |journal= |volume= |issue= |pages= |year= |pmid=28722872 |doi= |url=}}</ref>
*With improved techniques for tumor detection, the annual incidence has increased.
*About 80% to 90% of these tumors arise in the gastrinoma triangle.


===Age===
===Age===
*Zollinger-Ellison syndrome is a disease that tends to affect the middle-aged adult population (20-50 years of age).<ref name="pmid17108778">{{cite journal| author=Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT| title=Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. | journal=Medicine (Baltimore) | year= 2006 | volume= 85 | issue= 6 | pages= 295-330 | pmid=17108778 | doi=10.1097/01.md.0000236956.74128.76 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17108778  }} </ref>
*Zollinger-Ellison syndrome is a disease that tends to affect the middle-aged adult population (20 - 50 years of age).<ref name="pmid17108778">{{cite journal| author=Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT| title=Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. | journal=Medicine (Baltimore) | year= 2006 | volume= 85 | issue= 6 | pages= 295-330 | pmid=17108778 | doi=10.1097/01.md.0000236956.74128.76 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17108778  }} </ref>


===Gender===
===Gender===

Latest revision as of 15:12, 19 September 2019

Zollinger-Ellison syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Zollinger-Ellison syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Zollinger-Ellison syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Zollinger-Ellison syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Zollinger-Ellison syndrome epidemiology and demographics

CDC on Zollinger-Ellison syndrome epidemiology and demographics

Zollinger-Ellison syndrome epidemiology and demographics in the news

Blogs on Zollinger-Ellison syndrome epidemiology and demographics

Directions to Hospitals Treating Zollinger-Ellison syndrome

Risk calculators and risk factors for Zollinger-Ellison syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

The incidence of gastrinoma, which can cause Zollinger-Ellison syndrome, is approximately 0.05 - 0.2 per 100,000 individuals worldwide. About 25 to 30 percent of gastrinomas are caused by multiple endocrine neoplasia type 1 (MEN1).

Epidemiology and Demographics

Incidence

  • The worldwide incidence of gastrinomas is about 5 to 30 cases per 100,000 individuals per year.[1]
  • With improved techniques for tumor detection, the annual incidence has increased.
  • About 80% to 90% of these tumors arise in the gastrinoma triangle.

Age

  • Zollinger-Ellison syndrome is a disease that tends to affect the middle-aged adult population (20 - 50 years of age).[2]

Gender

  • Males are more commonly affected with Zollinger-Ellison syndrome than females.[2]

Race

  • There is no racial predilection to Zollinger-Ellison syndrome

References

  1. Cingam SR, Karanchi H. PMID 28722872. Missing or empty |title= (help)
  2. 2.0 2.1 Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT (2006). "Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature". Medicine (Baltimore). 85 (6): 295–330. doi:10.1097/01.md.0000236956.74128.76. PMID 17108778.

Template:WH Template:WS